CureFAKtor Pharmaceuticals LLC
This article was originally published in Start Up
Executive Summary
CureFAKtor Pharmaceuticals is one of a growing number of companies aimg to create effective cancer drugs by targeting an enzyme known as FAK, short for focal adhesion kinase, which like all kinases provides a binding site for ATP. Most commercial research on FAK has been oriented to blocking ATP as a way of slowing or stopping the growth of cancer cells, but CureFAKtor believes that the complexity of FAK's molecular structure offers the opportunity to block various sites, not just ATP, with an array of small molecules, and thus treat cancer by targeting multiple sites of interaction relevant to individual patient tumors.